44° Partly Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

14.18 -0.50 (-3.41%)

Streaming Delayed Price Updated: 3:44 PM EDT, Apr 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know ↗

Today 15:46 EDT

Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.

Via The Motley Fool

Topics Regulatory Compliance

Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment

April 13, 2026

THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its...

Via MarketMinute

Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data

April 09, 2026

In a major victory for its rare disease portfolio, Amgen (NASDAQ: AMGN) announced positive topline results on April 6, 2026, from its pivotal Phase 3 clinical trial evaluating a subcutaneous (SC)...

Via MarketMinute

Topics Intellectual Property

Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts ↗

January 07, 2025

Via Benzinga

Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views ↗

December 17, 2024

Via Benzinga

Which stocks are moving on Monday? ↗

April 06, 2026

Via Chartmill

Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones

April 02, 2026

The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that...

Via MarketMinute

Topics Intellectual Property

Which stocks are experiencing notable movement on Monday? ↗

March 30, 2026

Via Chartmill

Here are the top movers in Monday's session. ↗

March 30, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Monday's session. ↗

March 30, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 30, 2026

Via Chartmill

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Via The Motley Fool

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

Via The Motley Fool

Topics Regulatory Compliance

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.

Via The Motley Fool

Topics Regulatory Compliance

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

February 23, 2026

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Topics Regulatory Compliance

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗

January 02, 2026

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

Via The Motley Fool

Topics Regulatory Compliance

Viridian Therapeutics Inc (NASDAQ:VRDN) Shows High-Growth Momentum and Strong Technical Setup ↗

December 18, 2025

Viridian Therapeutics (VRDN) exemplifies the Minervini SEPA strategy, combining a strong technical uptrend with explosive fundamental sales and earnings growth momentum.

Via Chartmill

Expert Outlook: Viridian Therapeutics Through The Eyes Of 6 Analysts ↗

October 21, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results ↗

August 07, 2025

Via Benzinga

Viridian (VRDN) Q2 Net Loss Widens 55% ↗

August 06, 2025

Via The Motley Fool

What 5 Analyst Ratings Have To Say About Viridian Therapeutics ↗

May 07, 2025

Via Benzinga

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday ↗

December 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 16, 2024

Via Benzinga

9 Health Care Stocks With Whale Alerts In Today's Session ↗

December 16, 2024

Via Benzinga

Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday ↗

December 16, 2024

Via Benzinga

Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease ↗

December 16, 2024

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

Via Investor's Business Daily

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

Headline News about Viridian Therapeutics, Inc. - Common Stock

Sections

Services